Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/27/24
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?Zacks Investment Research • 02/23/24
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 02/21/24
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseGlobeNewsWire • 02/20/24
Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a BetZacks Investment Research • 02/06/24
Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerGlobeNewsWire • 02/06/24
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?Zacks Investment Research • 02/02/24
Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 01/01/24
Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to TradeZacks Investment Research • 12/25/23
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development ProgramGlobeNewsWire • 12/06/23
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development ProgramGlobeNewsWire • 12/05/23
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?Zacks Investment Research • 12/01/23
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer SymposiumGlobeNewsWire • 11/28/23
Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy OpportunitySeeking Alpha • 11/24/23
Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should KnowZacks Investment Research • 11/15/23
Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 11/13/23